Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. [electronic resource]
Producer: 20170718Description: 1010428317705509 p. digitalISSN:- 1423-0380
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab -- administration & dosage
- Colorectal Neoplasms -- blood
- Drug Resistance, Neoplasm -- genetics
- Female
- Hepatocyte Growth Factor -- blood
- Humans
- Male
- Middle Aged
- Neovascularization, Pathologic -- blood
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Vascular Endothelial Growth Factor A -- blood
- Vascular Endothelial Growth Factor Receptor-2 -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.